Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Vanguard Total Stock Market Index Fund ETF trades at $369. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Vanguard Total Stock Market Index Fund ETF pays none, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | VTI | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | — |
52-Week High | $812.27 | $374.36 |
52-Week Low | $545.46 | $305.74 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
VTI trades at $366.25, down 0.21% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF offers broad exposure to the entire U.S. stock market with over 3,500 holdings and a low 0.03% expense ratio. Recent news highlights its role in long-term portfolios and inclusion in new tax-advantaged accounts, emphasizing diversification benefits.
Outlook remains positive for long-term investors due to historical performance and cost efficiency, but near-term risks include market volatility and potential underperformance if large-cap tech stocks weaken. The bearish technical setup suggests caution for short-term traders, while fundamentals support holding for wealth accumulation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
